An announcement from Market Watch claims that Cougar Biotechnology has come to an agreement with the US Food & Drug Administration (FDA) to conduct an additional Phase III trial of abiraterone acetate in prostate cancer. The currently ongoing and much in demand Phase III trial of abiraterone acetate was designed for prostate cancer survivors who [...]
There is a lot of pressure on cancer survivors to participate in clinical trials. Without the brave individuals willing to participate in the trials research would grind to a halt along with new, improved treatments for all cancers. Even though an estimated 2.3 million people in the United States take part in clinical trials every [...]
Once we develop metastatic androgen-independent prostate cancer and experience disease progression after receiving docetaxel-based chemotherapy we have no approved treatment options. We have hit the proverbial wall! In the process of attempting to develop additional treatments, ImClone Systems Inc. (NASDAQ: IMCL), announced the beginning of a Phase II clinical trial for men with advanced prostate [...]
At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) has announced a new phase I/II clinical trial of Apoptone (HE3235) for late stage prostate cancer. Howard Scher, M.D., Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center said "The preclinical data generated to date suggest that Apoptone may offer a unique therapeutic approach to late-stage prostate cancer where [...]
